SUZHOU, China, May 25, 2025 /PRNewswire/ -- In May 2025, XellSmart Biopharmaceutical (Suzhou/Shanghai) Co., Ltd. officially announced that XellSmart-developed off-the-shelf allogeneic iPSC-derived subtype-specific neural regenerative cell therapy has received official approval from both...
Hence then, the article about world s first xellsmart s allogeneic ipsc derived regenerative cell therapy for spinal cord injury officially approved by the u s fda for a registrational phase i clinical trial was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( World's First -- XellSmart's Allogeneic iPSC-derived Regenerative Cell Therapy for Spinal Cord Injury Officially Approved by the U.S. FDA for a Registrational Phase I Clinical Trial )
Also on site :
- ‘The Final Girl Support Group’ Heads To Paramount As Feature To Be Directed & Adapted By Christopher Landon; Aperture & Muschiettis’ Double Dream Producing
- Marc Blumberg Arrested for Lewd Acts on a Child While Working at Moorpark Equestrian Facility; Additional Survivors Expected
- Inside China’s two-speed economy: Why goods consumption is slumping even as exports and services boom